The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

Table 2 Subgroup analyses of response rate

prognostic factor	events	n	I²	response rate(%)	95%CL	Q	p
Overall	125	178	0.584	67	53–79
Ag recognition moieties
CD19	118	169	62.6%	66	50–79
CD20	7	9	0%	70	39–89	0.05	0.8187
Disease
leukemia	90	125	50.3%	68	53–80
lymphoma	35	53	53.8%	61	53–77	0.21	0.6482
T cell origin
Autologous	116	157	53.9%	71	56–82
Allogeneic	9	21	50.7%	46	17–78	1.74	0.1873
Generation
1st	8	12	73%	61	7–97
2nd	116	159	55.7%	69	56–80	0.07	0.7928
costimulatory domains
CD137 and CD3ζ	49	63	36.1%	73	60–83
CD28 and CD3ζ	68	101	59.9%	65	45–80	0.52	0.4715
T cell activation
OKT3	86	105	42%	77	67–85
CD3/CD28 beads	29	51	58%	56	31–79	2.91	0.0882
IL-2 administration to cells
yes	42	75	67.5%	51	28–75
no	78	97	17.9%	77	65–85	3.62	0.057
Transfection methods
non-viral vector	2	5	4%	42	12–79
viral vector	123	173	61%	69	54–80	1.41	0.2345
Lymphodepletion
yes	98	127	34.1%	72	63–80
no	15	38	42.1%	44	28–62	4.2	0.0405
CART cells
≥ 10⁸	83	109	50.5%	72	56–84
< 10⁸	36	50	6.5%	66	52–78	0.31	0.5782
IL-2 administration to patients
yes	9	11	0%	72	44–90
no	122	167	67.9%	67	49–81	0.12	0.7293
T cell persistence time
≥ 2 months	92	117	0%	74	65–81
< 2 months	34	60	56.4%	50	27–73	3.59	0.0581
Peak serum IL-2 level
≥ 50 pg/mL	11	12	0%	85	55–96
< 50 pg/mL	5	16	56.6%	31	6–74	4.22	0.04

ISSN: 1471-2407